Skip to Main Content

On Monday, Editas Medicines announced that veteran biopharma executive James “Jim” Mullen was expanding his role with the gene-editing biotech, taking over as the new CEO while continuing as the company’s chairman — a role he’s held since March 2018.

Mullen replaces Cynthia Collins, who became Editas’ CEO in August 2019.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED